Ameneh Jafari

Dr. Ameneh Jafari

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 March 2024 in Cancer Medicine
Verified
Journal Article
Open access
AMAsma Manzari‐Tavakoli
Asma Manzari‐Tavakoli
ABAmirhesam Babajani
Amirhesam Babajani
MTMaryam Manzari Tavakoli
Maryam Manzari Tavakoli
FSFahimeh Safaeinejad
Fahimeh Safaeinejad
AJAmeneh Jafari
Ameneh Jafari
Cancer remains a leading cause of death worldwide, necessitating the development of innovative and more effective treatment strategies. Conventional cancer treatments often suffer from limitations such as systemic toxicity, poor pharmacokinetics, and drug resistance. Recently, there has been growing attention to utilizing natural compounds derived from various sources as possible cancer therapeutics. Natural compounds have demonstrated diverse bioactive properties, including antioxidant, anti‐inflammatory, and antitumor effects, making them attractive candidates for cancer treatment. However, their limited solubility and bioavailability present challenges for effective delivery to cancer cells. To overcome these limitations, researchers have turned to nanotechnology‐based drug delivery systems. Nanoparticles, with their small size and unique properties, can encapsulate therapeutic agents and offer benefits such as improved solubility, prolonged drug release, enhanced cellular uptake, and targeted delivery. Functionalizing nanoparticles with specific ligands further enhances their precision in recognizing and binding to cancer cells. Combining natural compounds with nanotechnology holds great promise in achieving efficient and safe cancer treatments by enhancing bioavailability, pharmacokinetics, and selectivity toward cancer cells. This review article provides an overview of the advancements in utilizing natural substances and nanotechnology‐based drug delivery systems for cancer treatment. It discusses the benefits and drawbacks of various types of nanoparticles, as well as the characteristics of natural compounds that make them appealing for cancer therapy. Additionally, current research on natural substances and nanoparticles in preclinical and clinical settings is highlighted. Finally, the challenges and future perspectives in developing natural compound‐nanoparticle‐based cancer therapies are discussed.

12 February 2021 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
AJAmeneh Jafari
Ameneh Jafari
MRMostafa Rezaei-Tavirani
Mostafa Rezaei-Tavirani
BFBehrouz Farhadihosseinabadi
Behrouz Farhadihosseinabadi
HZHakimeh Zali
Hakimeh Zali
HNHassan Niknejad
Hassan Niknejad
Cancer is a leading cause of death in both developed and developing countries, and because of population growth and aging, it is a growing medical burden worldwide. With robust development in medicine, the use of stem cells has opened new treatment modalities in cancer therapy. In adult stem cells, mesenchymal stem cells (MSCs) are showing rising promise in cancer treatment due to their unique properties. Among different sources of MSCs, human amniotic fluid/membrane is an attractive and suitable reservoir. There are conflicting opinions about the role of human amniotic membrane/fluid mesenchymal stem cells (hAMSCS/hAFMSCs) in cancer, as some studies demonstrating the anticancer effects of these cells and others suggesting their progressive effects on cancer. This review focuses on recent findings about the role of hAMSCs/hAFMSCs in cancer treatment and summarizes the suppressing as well as promoting effects of these cells on cancer progression and underling mechanisms.

6 June 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
AMAmir Hossein Mohammadi
Amir Hossein Mohammadi
SSSeyedvahid Seyedmoalemi
Seyedvahid Seyedmoalemi
MMMahsa Moghanlou
Mahsa Moghanlou
SASeyed Amirreza Akhlagh
Seyed Amirreza Akhlagh
SZSayyed Alireza Talaei Zavareh
Sayyed Alireza Talaei Zavareh
HMHamed Mirzaei
Hamed Mirzaei

24 September 2020 in Social Work in Public Health
Verified
Journal Article
Closed access
AJAmeneh Jafari
Ameneh Jafari
MRMostafa Rezaei-Tavirani
Mostafa Rezaei-Tavirani
MSMaryam Salimi
Maryam Salimi
RTReza Tavakkol
Reza Tavakkol
ZJZahra Jafari
Zahra Jafari
Oncological emergencies are defined as any acute possible morbid or life-threatening events in patients with cancer either because of the malignancy or because of their treatment. These events may occur at any time during malignancy, from symptoms present to end-stage disease. The aim of this study is the review of urgent conditions results from cancer or cancer treatment side effects that need to be addressed immediately. In this study, a comprehensive and in-depth narrative review was carried out by searching the databases of PubMed, Scopus, Science Direct, Google Scholar with the keywords of “cancer, emergency, metabolic emergency, neutropenic fever” along with the words, “tumor lysis syndrome, chemotherapeutic emergency, diagnosis, treatment “ in last two decades. Patients suffering from cancer mostly face the challenges that we are classified in different categories, including metabolic, hematologic, cardiovascular, neurologic, respiratory, infectious, and chemotherapeutic emergencies. These patients mostly complain of headaches, nausea, pain, and fever. In conclusion, knowledge of oncology emergencies and palliative care as part of a team approach is critical for treating cancer patients. In this light, it is pivotal for physicians to focus on the early detection of oncological emergencies. Moreover, training programs for cancer patients help them to timely recognize and report the oncologic emergency symptoms, leading to avoid deleterious consequences and unnecessary healthcare costs as well as improve the quality of life in these patients.

17 September 2022 in Molecular Therapy-Oncolytics
Verified
Journal Article
Open access
ARAli Rajabi
Ali Rajabi
MKMehrdad Kayedi
Mehrdad Kayedi
SRShiva Rahimi
Shiva Rahimi
FDFatemeh Dashti
Fatemeh Dashti
SMSeyed Mohammad Ali Mirazimi
Seyed Mohammad Ali Mirazimi
HMHamed Mirzaei
Hamed Mirzaei
Glioblastoma and gliomas can have a wide range of histopathologic subtypes. These heterogeneous histologic phenotypes originate from tumor cells with the distinct functions of tumorigenesis and self-renewal, called glioma stem cells (GSCs). GSCs are characterized based on multi-layered epigenetic mechanisms, which control the expression of many genes. This epigenetic regulatory mechanism is often based on functional non-coding RNAs (ncRNAs). ncRNAs have become increasingly important in the pathogenesis of human cancer and work as oncogenes or tumor suppressors to regulate carcinogenesis and progression. These RNAs by being involved in chromatin remodeling and modification, transcriptional regulation, and alternative splicing of pre-mRNA, as well as mRNA stability and protein translation, play a key role in tumor development and progression. Numerous studies have been performed to try to understand the dysregulation pattern of these ncRNAs in tumors and cancer stem cells (CSCs), which show robust differentiation and self-regeneration capacity. This review provides recent findings on the role of ncRNAs in glioma development and progression, particularly their effects on CSCs, thus accelerating the clinical implementation of ncRNAs as promising tumor biomarkers and therapeutic targets.

1 September 2020 in Risk Management and Healthcare Policy
Verified
Journal Article
Open access
PDF file
AJAmeneh Jafari
Ameneh Jafari
MRMostafa Rezaei-Tavirani
Mostafa Rezaei-Tavirani
SKSamira Karami
Samira Karami
MYMohsen Yazdani
Mohsen Yazdani
HZHakimeh Zali
Hakimeh Zali
ZJZahra Jafari
Zahra Jafari
New cases of the novel coronavirus, also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are increasing around the world. Currently, health care services are mainly focused on responding to and controlling the unique challenges of the coronavirus disease 2019 (COVID-19) pandemic. These changes, along with the higher susceptibility of patients with cancer to infections, have profound effects on other critical aspects of care and pose a serious challenge for the treatment of such patients. During the COVID-19 pandemic, it is important to provide strategies for managing the treatment of patients with cancer to limit COVID-19-associated risks at this difficult time. The present study set out to summarize the latest research on epidemiology, pathogenesis, and clinical features of COVID-19. We also address some of the current challenges associated with the management of patients with cancer during the COVID-19 pandemic and provide practical guidance to clinically deal with these challenges.